Obstructive Sleep Apnea, FDA

FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
FDA Approves Zepbound in Landmark Move to Battle Obstructive Sleep Apnea
The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and Drug Administration (FDA) has approved a drug
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first medication for certain patients with the condition.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
USA Today7d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
Zepbound is the first medication approved to treat patients with obstructive sleep apnea, said Sally Seymour, the FDA's director of the division of pulmonology, allergy and critical care.
SchaeffersResearch.com4d
2 Sleep Apnea Stocks in Focus Today
The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...